Idiosyncratic drug-induced agranulocytosis: Update of an old disorder

European Journal of Internal Medicine

Volumn 17, Issue 8, 2006, Pages 529-535

  Andrès, Emmanuel ^a,b   Zimmer, Jacques ^b,c   Affenberger, Stéphane ^a,b   Federici, Laure ^a,b   Alt, Martine ^b,c   Maloisel, Frédéric ^a,b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Pharmacovigilance Center of Alsace   (France)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Clinical manifestations; Drug induced agranulocytosis; Epidemiology; Hematopoietic growth factors; Idiosyncratic agranulocytosis; Neutropenia; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXAPINE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; ANTITHYROID AGENT; BENOXAPROFEN; BETA LACTAM ANTIBIOTIC; CARBIMAZOLE; CARDIOVASCULAR AGENT; CEPHALOSPORIN DERIVATIVE; CHLORDIAZEPOXIDE; CLOZAPINE; COTRIMOXAZOLE; DIAZEPAM; DIFLUNISAL; FENOPROFEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SALAZOSULFAPYRIDINE; TICLOPIDINE; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; AGRANULOCYTOSIS; BLOOD TOXICITY; CLINICAL TRIAL; COHORT ANALYSIS; COMA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EXPOSURE; EDEMA; FRANCE; HEALTH PRACTITIONER; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY FAILURE; LIFE EXPECTANCY; MEDICAL RESEARCH; METABOLIC DISORDER; MORTALITY; MYELODYSPLASIA; NECROSIS; NEUTROPENIA; NEUTROPHIL COUNT; OBSTRUCTION; PATHOPHYSIOLOGY; PNEUMONIA; PROGNOSIS; REVIEW; SENESCENCE; SEPSIS; SEPTIC SHOCK; SEPTICEMIA; UNIVERSITY HOSPITAL;

EID: 34248655834     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2006.07.012     Document Type: Review

References (49)

1. Schultz W. Ueber eigenartige halserkrankungen. Dtsch Med Wochenschr 48 (1922) 1495-1496
2. Andrès E., Kurtz J.E., and Maloisel F. Non-chemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature. Clin Lab Haematol 24 (2002) 99-106
3. Young N.S., and Alter B.F. Agranulocytosis. Aplastic anemia, acquired and inherited (1993), WB Saunders Co, Philadelphia, Pa 227-264
4. Andrès E., Maloisel F., Kaltenbach G., Noel E., Alt M., and le Groupe d'étude des agranulocytoses médicamenteuses des Hôpitaux Universitaires de Strasbourg. Agranulocytoses médicamenteuses: données actuelles. Ann Biol Clin 61 (2003) 121-124
5. Bénichou C., and Solal-Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. Nouv Rev Fr Hematol 33 (1993) 257-262
6. Dale D.C., Guerry IV D., Wewerka J.R., Bull J.M., and Chusid M.J. Chronic neutropenia. Medicine (Baltimore) 58 (1979) 128-144
7. Patton W.N., and Duffull S.B. Idiosyncratic drug-induced haematological abnormalities: incidence, pathogenosis, management and avoidance. Drug Safety 11 (1994) 445-462
8. Claas F.H. Immune mechanisms leading to drug-induced blood dyscrasias. Eur J Haematol 60 (1996) 64-68 [suppl]
9. Guest I., and Uetrecht. Drugs that induce neutropenia/agranulocytosis may target specific component of the stromal cell extracellular matrix. Med Hypotheses 53 (1999) 145-151
10. Salama A., Schütz B., Kiefel V., Breithaupt H., and Mueller-Eckhardt C. Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 72 (1989) 127-132
11. Lewitt L.J. Chlorpropamide-induced pure white cell aplasia. Blood 69 (1987) 394-400
12. Gerson W.T., Fine D.G., Spielberg S.P., and Sensenbrenner L.L. Anticonvulsivant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood 61 (1983) 889-893
13. Iverson S., Zahid N., and Uetrecht J.P. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chem Biol Interact 142 (2002) 175-199
14. Nyfeler B., and Pichler W.J. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 27 (1997) 175-181
15. Young N.S. Drug-related blood dyscrasias. Eur J Haematol 60 (1996) 6-8 [suppl]
16. Mosyagin I., Dettling M., Roots I., Mueller-Oerlinghausen B., and Cascorbi I. Impact of myeloperoxidase and NADPH-oxydase polymorphism in drug-induced agranulocytosis. J Clin Psychopharmacol 24 (2004) 613-617
17. Andrès E., and Maloisel F. Drug-associated agranulocytosis: experience at Strasbourg Teaching Hospital. Arch Intern Med 159 (1999) 2366-2367
18. Strom B.L., Carson J.L., Schinnar R., Snyder E.S., and Shaw M. Descriptive epidemiology of agranulocytosis. Arch Intern Med 152 (1992) 1475-1480
19. Andrès E., Maloisel F., Kurtz J.E., Kaltenbach G., Alt M., Weber J.C., et al. Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med 13 (2002) 324-328
20. Andrès E., Noel E., Kurtz J.E., Henoun Loukili N., Kaltenbach G., and Maloisel F. Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients. Drugs Aging 21 (2004) 427-435
21. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 256 (1986) 1749-1757
22. Kelly J.P., Kaufman D.W., and Shapiro S. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: the International Agranulocytosis and Aplastic Anemia Study. Clin Pharmacol Ther 49 (1991) 330-341
23. Paitel J.F., Stockemer V., Dorvaux V., Witz F., Guerci A., and Lederlin P. Agranulocytoses aiguës médicamenteuses. Etude clinique à propos de 30 patients et évolution des étiologies sur 2 décennies. Rev Med Interne 16 (1995) 495-499
24. Vial T., Pofilet C., Pham E., Payen C., and Evreux J.C. Agranulocytoses aiguës médicamenteuses: expérience du Centre Régional de Pharmacovigilance de Lyon sur 7 ans. Therapie 51 (1996) 508-515
25. Shapiro S., Issaragrisil S., Kaufman D.W., Anderson T., Chansung K., Thamprasit T., et al. Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am J Trop Med Hyg 60 (1999) 573-577
26. Van der Klauw M.M., Goudsmit R., Halie M.R., van't Veer M.B., Herings R.M., Wilson J.H., et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 159 (1999) 369-374
27. Van der Klauw M.M., Wilson J.H., and Stricker B.H. Drug-associated agranulocytosis: 20 years of reporting in the Netherlands (1974-1994). Am J Hematol 57 (1998) 206-211
28. International Agranulocytosis and Aplastic Anaemia Study. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. BMJ 297 (1988) 262-265
29. Hodinka L., Geher P., Meretey K., Gyodi E.K., Petranyi G.G., and Boszoky S. Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies. Int Arch Allergy Appl Immunol 65 (1981) 460-464
30. Dettling M., Cascorbi I., Roots I., and Mueller-Oerlinghausen B. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Arch Gen Psychiatry 58 (2001) 93-94
31. Singhvi S.M., Duchin K.L., Willard D.A., McKinstry D.N., and Migdalof B.H. Renal handling of captopril: effect of probenecid. Clin Pharmacol Ther 32 (1982) 182-189
32. Julia A., Olona M., Bueno J., Revilla E., Rosselo J., Petit J., et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Hematol 79 (1991) 366-372
33. Kaufman D.W., Kelly J.P., Levy M., and Shapiro S. The drug etiology of agranulocytosis and aplastic anaemia (1991), Oxford University Press, Oxford 148-158
34. Andrès E., Maloisel F., Kurtz J.E., Vinzio S., Sibilia J., Schlienger J.L., et al. Les facteurs de croissance hématopoïétique ont-ils une place dans le traitement des agranulocytoses médicamenteuses?. Rev Med Interne 21 (2000) 580-585
35. Kurtz J.E., Andrès E., Maloisel F., Kurtz-Illig V., Heitz D., Sibilia J., et al. Drug-induced agranulocytosis in elderly. A case series of 25 patients. Age Aging 28 (1999) 325-326
36. Tajiri J., Noguchi S., Murakami T., and Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 150 (1990) 621-624
37. Tajiri J. Antithyroid drug-induced agranulocytosis: special reference to normal white cell count agranulocytosis. Thyroid 14 (2004) 459-462
38. Rudivic R., and Jelic S. Haematological aspects of drug-induced agranulocytosis. Scand J Haematol 9 (1972) 18-27
39. Maloisel F., Andrès E., Kaltenbach G., Noel E., Martin-Hunyadi C., and Dufour P. Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis. A study of 91 patients from a single center. Presse Med 33 (2004) 1164-1168
40. Shastri K.A., and Logue G.L. Autoimmune neutropenia. Blood 81 (1993) 1984-1995
41. Andrès E., Kurtz J.E., Perrin A.E., Dufour P., Schlienger J.L., and Maloisel F. The use of haematopoietic growth factors in antithyroid-related drug-induced agranulocytosis: a report of 20 patients. Q J Med 94 (2001) 423-428
42. Andrès E., Kurtz J.E., Martin-Hunyadi C., Kaltenbach G., Alt M., Weber J.C., et al. Non-chemotherapy drug-induced agranulocytosis in elderly patients: the effects of Granulocyte Colony-Stimulating Factor. Am J Med 112 (2002) 460-464
43. Sprikkelman A., de Wolf J.T.M., and Vellenga E. Application of haematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia 8 (1994) 2031-2036
44. Beauchesne M.F., and Shalansky S.J. Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy 19 (1999) 299-305
45. Andrès E., Noel E., and Maloisel F. Nonchemotherapy drug-induced agranulocytosis: interest of hematopoietic growth factors. J Intern Med 251 (2002) 533-534
46. Palmblad J., Papadaki H.A., and Eliopoulos G. Acute and chronic neutropenias. What is new?. J Intern Med 250 (2001) 476-491
47. Fukata S., Kuma K., and Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroïd 9 (1999) 29-31
48. Andrès E., Noel E., and Maloisel F. Long-term outcome of patients treated with hematopoietic growth factors for idiosyncratic drug-induced agranulocytosis. Am J Med 116 (2004) 354
49. Bhatt V., and Saleem A. Drug-induced neutropenia-pathophysiology, clinical features, and management. Ann Clin Lab Sci 34 (2004) 131-137